Robin Rohm, CEO and Co-Founder of Apheris, joins Ross Katz to explore how federated learning is unlocking secure, cross-company collaboration in pharma. Discover how Apheris is enabling biopharma leaders to train cutting-edge co-folding models without sharing sensitive data, why AlphaFold 3 wasn’t enough, and what OpenFold 3 means for the future of AI in drug discovery.

​​What You'll Learn in This Episode

>> Why federated learning is a game-changer for pharma data sharing and AI-driven research

>> How OpenFold 3 builds on AlphaFold’s legacy to solve the protein-ligand interaction challenge

>> The role of structural benchmarking in model development and validation

>> How Apheris enables privacy-preserving collaboration between major pharma players

>>The importance of high-quality, proprietary datasets in advancing co-folding model accuracy

Meet Our Guest

Robin Rohm is the CEO and Co-Founder of Apheris, a leader in federated data networks for life sciences. With a background in mathematics and computational genomics, Robin is advancing secure AI collaboration in pharma and biotech.

About The Host

Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation.

Connect with Our Guest:

• Sponsor: CorrDyn, a data consultancy
• Connect with Robin Roehm on LinkedIn

Connect with Us:

• Follow the podcast for more insightful discussions on the latest in biotech and data science.
• Subscribe and leave a review if you enjoyed this episode!
• Connect with Ross Katz on LinkedIn

Sponsored by…

This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.